Ferronova's vision is to produce the world's best and most sensitive medical magnetic nano-particles and detectors. Our nano-particles provide up to three times the magnetism of iron-oxide particles, enabling greater depth of detection and better MRI contrast, and overcome problems associated with other magnetic particles including clearance from the injection site. Our research partners at Victoria University in Wellington New Zealand, the University of New South Wales in Sydney Australia, and UniSA Future Industries Institute in Adelaide Australia continue to research particles, coatings, and clinical applications to improve outcomes in cancer diagnostics and therapeutics.
The technology is targeted at Sentinel Lymph Node Biopsy (SLNB). It is designed to meet the needs of surgeons treating difficult cancers such as head and neck cancer, prostate cancer, and colo-rectal cancer. The unique particles are designed to be retained in the sentinel node, be compatible with existing surgical equipment, and to overcome false negatives associated with shine-through, where sentinel lymph nodes close to an injection site can be missed due to inadequate resolution of alternative solutions.
*The probe and tracer are not regulatory approved or cleared in any markets.
The magnetic particles are designed to work in conjunction with the our probe and other manufacturers existing surgical equipment, eliminating the logistical and handling issues associated with alternative radioisotope tracers. The magnetic technology is well suited to complex cancers such as head and neck cancer, prostate cancer, and colo-rectal cancer where resolution and the ability to locate sentinel lymph nodes close to the injection site is of critical importance.
Using magnetic tracers instead of radioisotopes, our ultra-sensitive magnetometer probe provides high spatial resolution, enabling detection of sentinel lymph
nodes close to the injection site or where lymph nodes are close together.